Intraductal proliferative lesions of the breast: Morphology, associated risk and molecular biology

Modern Pathology

Volumn 23, Issue SUPPL. 2, 2010, Pages

  Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Atypical hyperplasia; Breast; Columnar cell lesions; Ductal carcinoma in situ; Usual hyperplasia

Indexed keywords

COLLAGEN TYPE 4; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; LAMININ; PROGESTERONE RECEPTOR;

ATYPICAL DUCTAL HYPERPLASIA; BREAST BIOPSY; BREAST CALCIFICATION; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; BREAST LESION; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORPHOLOGY; CANCER RISK; CELL STRUCTURE; CHROMOSOME 16Q; CHROMOSOME 1Q; DUCTAL HYPERPLASIA; FLAT EPITHELIA ATYPIA; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MOLECULAR BIOLOGY; NEEDLE BIOPSY; NOMENCLATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; MOLECULAR BIOLOGY; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 77951992183     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.56     Document Type: Review

References (23)

1. Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat 1993;28:157-166.
2. Van Dongen JA, Holland R, Peterse JL, et al. Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer 1992;28:626-629.
3. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv Anat Pathol 2003;10:113-124.
4. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005;205:248-254.
5. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005;29:734-746.
6. Abdel-Fatah TMA, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007;13:417-426.
7. Lakhani SR, Collins N, Stratton MR, et al. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48:611-615.
8. Ellis IO, Pinder SE, Elston CW. A critical appraisal of existing classification systems of epithelial hyperpla-sia and in situ neoplasia of the breast with proposals for future methods of categorization: where are we going? Semin Diagn Pathol 1999;16:202-208.
9. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-2708.
10. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomar-kers Prev 1997;6:297-301.
11. Pathology Reporting of Breast Disease. NHSBSP and RCPath. A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. NHSBSP Publication No. 58, 2005.
12. European, Community. European Guidelines for Quality Assurance in Mammographic Screening, 2nd edn. Office for Official Publications of the European Communities: Luxembourg, 1996.
13. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Inter-observer reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992;16:1133-1143.
14. Schnitt SJ. The diagnosis and management of pre-invasive breast disease: flat epithelial atypia-classifi-cation, pathologic features and clinical significance. Breast Cancer Res 2003;5:263-268.
15. Holland R, Hendriks JHCL, Vebeek ALM, et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990;335:519-522.
16. Page DL, Dupont WD, Rogers LW, et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-1200.
17. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990;70:853-871.
18. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-2274.
19. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223-235.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
21. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
22. Buerger H, Mommers EC, Littmann R, et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 2001;194:165-170.
23. Ellis IO, Humphreys S, Michell M, et al., UK National Coordinating Committee for Breast Screening Pathology; European Commission Working Group on Breast Screening Pathology. Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol 2004;57:897-902.